Institut National de la Santé et de la Recherche Médicale UMR 1037, Equipe 4, Centre de Recherches en Cancérologie de Toulouse, CHU Rangueil, BP84225, 31432 Toulouse, France.
PLoS One. 2011;6(8):e23315. doi: 10.1371/journal.pone.0023315. Epub 2011 Aug 17.
Photochemotherapy is used both for solid tumors and in extracorporeal treatment of various hematologic disorders. Nevertheless, its development in oncology remains limited, because of the low selectivity of photosensitizers (PS) towards human tumor cells. To enhance PS efficiency, we recently covalently linked a porphyrin (TrMPyP) to a plant lectin (Morniga G), known to recognize with high affinity tumor-associated T and Tn antigens. The conjugation allowed a quick uptake of PS by Tn-positive Jurkat leukemia cells and efficient PS-induced phototoxicity. The present study was performed: (i) to evaluate the targeting potential of the conjugate towards tumor and normal cells and its phototoxicity on various leukemia cells, (ii) to investigate the mechanism of conjugate-mediated cell death. The conjugate: (i) strongly increased (×1000) the PS phototoxicity towards leukemic Jurkat T cells through an O-glycan-dependent process; (ii) specifically purged tumor cells from a 1∶1 mixture of Jurkat leukemia (Tn-positive) and healthy (Tn-negative) lymphocytes, preserving the activation potential of healthy lymphocytes; (iii) was effective against various leukemic cell lines with distinct phenotypes, as well as fresh human primary acute and chronic lymphoid leukemia cells; (iv) induced mostly a caspase-independent cell death, which might be an advantage as tumor cells often resist caspase-dependent cell death. Altogether, the present observations suggest that conjugation with plant lectins can allow targeting of photosensitizers towards aberrant glycosylation of tumor cells, e.g. to purge leukemia cells from blood and to preserve the normal leukocytes in extracorporeal photochemotherapy.
光化学疗法既用于实体瘤,也用于各种血液系统疾病的体外治疗。然而,由于光敏剂(PS)对人肿瘤细胞的选择性低,其在肿瘤学中的发展仍然受到限制。为了提高 PS 的效率,我们最近将卟啉(TrMPyP)与一种植物凝集素(Morniga G)共价连接,已知该凝集素能够高度识别与肿瘤相关的 T 和 Tn 抗原。该缀合物允许 Tn 阳性 Jurkat 白血病细胞快速摄取 PS,并有效诱导 PS 光毒性。本研究旨在:(i)评估该缀合物对肿瘤和正常细胞的靶向潜力及其对各种白血病细胞的光毒性,(ii)研究该缀合物介导细胞死亡的机制。该缀合物:(i)通过 O-聚糖依赖性过程,将 PS 对白血病 Jurkat T 细胞的光毒性提高了 1000 倍;(ii)特异性地从 Jurkat 白血病(Tn 阳性)和健康(Tn 阴性)淋巴细胞的 1∶1 混合物中清除肿瘤细胞,同时保持健康淋巴细胞的激活潜力;(iii)对具有不同表型的各种白血病细胞系以及新鲜的人类原发性急性和慢性淋巴细胞白血病细胞均有效;(iv)诱导的主要是一种 caspase 非依赖性细胞死亡,这可能是一种优势,因为肿瘤细胞通常会抵抗 caspase 依赖性细胞死亡。总之,目前的观察结果表明,与植物凝集素缀合可以将光敏剂靶向肿瘤细胞的异常糖基化,例如从血液中清除白血病细胞,并在体外光化学疗法中保留正常白细胞。